The protective effect of vildagliptin in chronic experimental cyclosporine A-induced hepatotoxicity

Canadian Journal of Physiology and Pharmacology

Volumn 94, Issue 3, 2015, Pages 251-256

  El Sherbeeny, Nagla A ^a,b   Nader, Manar A ^a,c  

^a TAIBAH UNIVERSITY   (Saudi Arabia)

^b Suez Canal University Faculty of Medicine   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Apoptosis; Cyclosporine; Inflammation; Oxidative stress; Vildagliptin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CATALASE; CYCLOSPORIN A; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; PROTEIN BAX; PROTEIN BCL 2; SERUM ALBUMIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VILDAGLIPTIN; ADAMANTANE; ANTIOXIDANT; CYCLOSPORIN; NITRILE; PROTECTIVE AGENT; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; LIVER FUNCTION; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG EFFECTS; LIPID PEROXIDATION; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

ADAMANTANE; ALANINE TRANSAMINASE; ANIMALS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; CATALASE; CHEMICAL AND DRUG INDUCED LIVER INJURY; CYCLOSPORINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LIPID PEROXIDATION; LIVER; MALE; NITRILES; OXIDATIVE STRESS; PROTECTIVE AGENTS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84959346321     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2015-0336     Document Type: Article

References (41)

1. Andres, D., Diez-Fernandez, C., Castrillo, A., and Cascales, M. 2002. Relationship between the activation of heat shock factor and the suppression of nuclear factor-_B activity in rat hepatocyte cultures treated with cyclosporine A. Biochem. Pharmacol. 64(2): 247–256. doi:10.1016/S0006-2952(02)01115-2.
2. Apaijai, N., Chinda, K., Palee, S., Chattipakorn, S., and Chattipakorn, N. 2014. Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. PLoS One, 9(7): e102374. doi:10.1371/journal.pone.0102374.
3. Avila Dde, L., Araujo, G.R., Silva, M., Miranda, P.H., Diniz, M.F., Pedrosa, M.L., et al. 2013. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats. Arch. Med. Res. 44(3): 194–202. doi:10.1016/j.arcmed.2013.03.004.
4. Balaban, Y.H., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., et al. 2007. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann. Hepatol. 6(4): 242–250.
5. Barnett, A. 2006. DPP-4 inhibitors and their potential role in the management of type-2 diabetes. Int. J. Clin. Pract. 60(11): 1454–1470. doi:10.1111/j.1742-1241. 2006.01178.x.
6. Chinda, K., Sanit, J., Chattipakorn, S., and Chattipakorn, N. 2014. Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart. Diab. Vasc. Dis. Res. 11(2): 75–83. doi:10.1177/1479164113516134.
7. Czaja, M.J. 2007. Cell signaling in oxidative stress-induced liver injury. Semin. Liver Dis. 27(4): 378–389. doi:10.1055/s-2007-991514.
8. Das, S.S., Hayashi, H., Sato, T., Yamada, R., Hiratsuka, M., and Hirasawa, N. 2014. Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose. Diabetes Metab. Syndr. Obes. 7: 185–194. doi:10.2147/DMSO.S62610.
9. Duruibe, V.A., Okonmah, A., and Blyden, G.T. 1989. Effect of cyclosporin on rat liver and kidney glutathione content. Pharmacology, 39(4): 205–212. doi:10. 1159/000138599.
10. El-Sokkary, G.H., Abdel-Rahman, G.H., and Kamel, E.S. 2005. Melatonin protects against lead-induced hepatic and renal toxicity in male rats. Toxicology, 213(1–2): 25–33. doi:10.1016/j.tox.2005.05.003.
11. Fournier, N., Ducet, G., and Crevat, A. 1987. Action of cyclosporine on mitochondrial calcium fluxes. J. Bioenerg. Biomembr. 19(3): 297–303. doi:10.1007/BF00762419.
12. Gaetaniello, L., Fiore, M., de Filippo, S., Pozzi, N., Tamasi, S., and Pignata, C. 1998. Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells. Hepatology, 27(4): 934–942. doi:10.1002/hep.510270407.
13. Ghadermarzi, M., and Moosavi-Movahedi, A.A. 1996. Determination of the kinetic parameters for the “suicide substrate” inactivation of bovine liver catalase by hydrogen peroxide. J. Enzyme Inhib. 10(3): 167–175. doi:10.3109/14756369609030310.
14. Goksu Erol, A.Y., Avcı, G., Sevimli, A., Ulutas, E., and Ozdemir, M. 2013. The protective effects of omega 3 fatty acids and sesame oil against cyclosporine A-induced nephrotoxicity. Drug Chem. Toxicol. 36(2): 241–248. doi:10.3109/01480545.2012.710627.
15. Gorrell, M.D., Gysbers, V., and McCaughan, G.W. 2001. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 54(3): 249–264. doi:10.1046/j.1365-3083.2001.00984.x.
16. Itou, M., Kawaguchi, T., Taniguchi, E., and Sata, M. 2013. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J. Gastroenterol. 19(15): 2298–2306. doi:10.3748/wjg.v19.i15.2298.
17. Jiang, X., and Wang, X. 2004. Cytochrome C-mediated apoptosis. Annu. Rev. Biochem. 73: 87–106. doi:10.1146/annurev.biochem.73.011303.073706.
18. Josephine, A., Nithya, K., Amudha, G., Veena, C.K., Preetha, S.P., and Varalakshmi, P. 2008. Role of sulphated polysaccharides from Sargassum Wightii in Cyclosporine A-induced oxidative liver injury in rats. BMC Pharmacol. 8: 4. doi:10.1186/1471-2210-8-4.
19. Kwak, C.S., and Mun, K.C. 2000. The beneficial effect of melatonin for cyclosporine hepatotoxicity in rats. Transplant. Proc. 32(7): 2009–2010. doi:10.1016/S0041-1345(00)01535-9.
20. Lee, J. 2010. Use of antioxidants to prevent cyclosporine a toxicity. Toxicol. Res. 26(3): 163–170. doi:10.5487/TR.2010.26.3.163.
21. Liu, W.J., Xie, S.H., Liu, Y.N., Kim, W., Jin, H.Y., Park, S.K., et al. 2012. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 340(2): 248–255. doi:10.1124/jpet.111. 186866.
22. Luedde, T., and Schwabe, R.F. 2011. NF-κB in the liver-linking injury, fibrosis and hepatocellularcarcinoma. Nat. Rev. Gastroenterol. Hepatol. 8(2): 108–118. doi: 10.1038/nrgastro.2010.213.
23. McCashland, T.M., Donovan, J.P., Amelsberg, A., Rossi, S.S., Hofmann, A.F., Shaw, B.W., Jr., and Quigley, E.M. 1994. Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: differing effects of cyclosporine and FK 506. Hepatology, 19(6): 1381–1389. doi:10.1002/hep. 1840190611.
24. Mentzel, S., Dijkman, H.B., Van Son, J.P., Koene, R.A., and Assmann, K.J. 1996. Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J. Histochem. Cytochem. 44(5): 445–461. doi:10.1177/44.5.8627002.
25. Miyagawa, K., Kondo, T., Goto, R., Matsuyama, R., Ono, K., Kitano, S., et al. 2013. Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Cardiovasc. Diabetol. 12: 160. doi:10.1186/1475-2840-12-160.
26. Moran, D., De Buitrago, J.M., Fernandez, E., Galan, A.I., Munoz, M.E., and Jimenez, R. 1998. Inhibition of biliary glutathione secretion by cyclosporine A in the rat: possible mechanisms and role in the cholestasis induced by the drug. J. Hepatol. 29(1): 68–77. doi:10.1016/S0168-8278(98)80180-3.
27. Nicolli, A., Basso, E., Petronilli, V., Wenger, R.M., and Bernard, P. 1995. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore and cyclosporine A-sensitive channel. J. Biol. Chem. 271(4): 2185–2192.
28. Rezzani, R. 2004. Cyclosporine A and adverse effects on organs: histochemical studies. Prog. Histochem. Cytochem. 39(2): 85–128. doi:10.1016/j.proghi.2004. 04.001.
29. Rezzani, R., Rodella, L., and Bianchi, R. 2001. Melatonin antagonises the cyclosporine A immunosuppressive effects in rat thymuses. Int. Immunopharmacol. 1(8): 1615–1619. doi:10.1016/S1567-5769(01)00077-7.
30. Rezzani, R., Buffoli, B., Rodella, L., Stacchiotti, A., and Bianchi, R. 2005. Protective role of melatonin in cyclosporine A-induced oxidative stress in rat liver. Int. Immunopharmacol. 5(9): 1397–1405. doi:10.1016/j.intimp.2005.03.021.
31. Salducci, M.D., Chauvet-Monges, A.M., Berland, Y., Dussol, B., Elsen, R., and Crevat, A. 1992. The restoration of ATP synthesis may explain the protective effect of calcium antagonist against cyclosporine A nephrotoxicity. Life Sci. 50(26): 2053–2058. doi:10.1016/0024-3205(92)90571-6.
32. Serino, F., Grevel, J., Napoli, K.L., Kahan, B.D., and Strobel, H.W. 1994. Oxygen radical formation by the cytochrome P450 system as a cellular mechanism for cyclosporine toxicity. Transplant. Proc. 26(5): 2869–2870.
33. Shihab, F.S., Andoh, T.F., Tanner, A.M., Yi, H., and Bennett, W.M. 1999. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int. 56(6): 2147–2159. doi:10.1046/j.1523-1755.1999. 00794.x.
34. Tarantino, G., and Finelli, C. 2013. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J. Gastroenterol. 19(22): 3375–3384. doi:10.3748/wjg.v19.i22.3375.
35. Tarantino, G., Colao, A., Capone, D., Conca, P., Tarantino, M., and Grimaldi, E. 2011a. Circulating levels of cytochrome C, gammaglutamyl transferase, triglycerides and unconjugated bilirubin inoverweight/obese patients with nonalcoholic fatty liver disease. J. Biol. Regul. Homeost. Agents, 25(1): 47–56.
36. Tarantino, G., Scopacasa, F., Colao, A., Capone, D., Tarantino, M., Grimaldi, E., et al. 2011b. Serum Bcl2 concentrations in overweightobese subjects with nonalcoholic fatty liver disease. World J. Gastroenterol. 17(48): 5280–5288. doi:10.3748/wjg.v17.i48.5280.
37. Vavrinec, P., Henning, R.H., Landheer, S.W., Wang, Y., Deelman, L.E., van Dokkum, R.P., et al. 2014. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in Zucker Diabetic Fatty rat. Curr. Vasc. Pharmacol. 12(6): 836–844. doi:10.2174/15701611113116660151.
38. Wei, M.C., Zong, W.X., Cheng, E.H., Lindsten, T., Panoutsakopoulou, V., Ross, A.J., et al. 2001. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science, 292(5517): 727–730. doi:10.1126/science.1059108.
39. Wixson, S.K., White, W.J., Hughes, H.C., Jr., Lang, C.M., and Marshall, W.K. 1987. A comparison of pentobarbital, fentanyl-droperidol, ketamine-xylazine and ketamine-diazepam anesthesia in adult male rats. Lab. Anim. Sci. 37(6): 726–730.
40. Wu, Y.J., Guo, X., Li, C.J., Li, D.Q., Zhang, J., Yang, Y., et al. 2015. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism, 64(2): 226–235. doi:10.1016/j.metabol.2014.08.006.
41. Zhu, W., and Fung, P.C. 2000. The roles played by crucial free radicals like lipid free radicals, nitric oxide, and enzymes NOS and NADPH in CCl4-induced acute liver injury of mice. Free Radic. Biol. Med. 29(9): 870–880. doi:10.1016/S0891-5849(00)00396-8.